New approaches and prospects of immunotherapy and gene therapy for prostate cancer

Abstract

Prostate cancer stands as the most prevalent cancer globally, constituting 21% of all cancer diagnoses in male patients. Urgent optimization of prostate cancer care is essential, given that this disease claims 345,000 lives every year. These innovative approaches hold substantial promise for both researchers and patients, representing a beacon of hope in the inhibitory act against prostate cancer. Prostate cancer's gradual advancement deems it suitable for immune therapy, but trials in metastatic cases show limited effectiveness, likely due to compromised immunity. Hindered by defective cellular responses, an immune-suppressive microenvironment, emerging evidence and breakthroughs, such as CAR-T therapy, inspire cautious optimism for advanced prostate cancer immunotherapy. Tumors utilize tactics to escape immune recognition, promoting the proliferation of MDSCs, Treg cells, and TAMs. Immunotherapy targets prostate cancer by mostly expressed target proteins and overexpressed target proteins. Immune cells play a role in tumor development and metastasis in advanced prostate cancer. Modulating the tumor microenvironment presents therapeutic possibilities. Certain prostate cancer types exhibit potential responses to immune checkpoint inhibitors, yet obstacles remain, necessitating additional research for enhanced efficacy. Immunotherapy faces hurdles in prostate cancer - limited inflammation, scarce antigens, and a resistant microenvironment. Grasping resistance intricacies is pivotal. The identification of DNA's helical structure propelled global progress in disease treatment through gene therapy. Choosing gene therapy vectors is critical; viruses are potent but toxic, while nonviral options, though less toxic, encounter barriers affecting transfection. In the realm of prostate cancer treatment, immunotherapy and gene therapy are emerging as increasingly viable options.

Keywords

Immunotherapy / gene therapy / prostate cancer / tumor microenvironment / immune checkpoint inhibitor

References

[1] Rehman LU,Fatima W.Immunotherapy for prostate cancer: a current systematic review and patient centric perspectives.J Clin Med2023;12:1446 PMCID:PMC9966657

[2] Tewari AK,Yadav SS,Khan I.Inflammation and prostate cancer.Adv Exp Med Biol2018;1095:41-65

[3] Gurel B,Thompson IM Jr.Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.Cancer Epidemiol Biomarkers Prev2014;23:847-56 PMCID:PMC4012292

[4] Sfanos KS.Prostate cancer and inflammation: the evidence.Histopathology2012;60:199-215 PMCID:PMC4029103

[5] Sfanos KS,De Marzo AM.Infections and inflammation in prostate cancer.Am J Clin Exp Urol2013;1:3-11 PMCID:PMC4219279

[6] Cai T,Tamanini I.Current knowledge of the potential links between inflammation and prostate cancer.Int J Mol Sci2019;20:3833 PMCID:PMC6696519

[7] Saxby H,Mikropoulos C.Androgen receptor gene pathway upregulation and radiation resistance in oligometastatic prostate cancer.Int J Mol Sci2022;23:4786 PMCID:PMC9105839

[8] Sfanos KS,Maris CH.Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.Clin Cancer Res2008;14:3254-61 PMCID:PMC3082357

[9] Bubendorf L,Wagner U.Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.Hum Pathol2000;31:578-83

[10] Bilusic M,Gulley JL.Immunotherapy of prostate cancer: facts and hopes.Clin Cancer Res2017;23:6764-70 PMCID:PMC5690854

[11] Markowski MC,Eisenberger MA.Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.Prostate2020;80:407-11 PMCID:PMC7585736

[12] Motzer RJ,McDermott DF.Nivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med2015;373:1803-13 PMCID:PMC5719487

[13] Luke JJ,Queirolo P.Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.Lancet2022;399:1718-29

[14] Motzer RJ,McDermott DF.Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.N Engl J Med2018;378:1277-90

[15] Larkin J,Gonzalez R.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N Engl J Med2015;373:23-34

[16] Petrylak DP,Chi KN.Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.Lancet2017;390:2266-77

[17] Lee NY,Psyrri A.Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.Lancet Oncol2021;22:450-62

[18] Boussios S,Shah S,Sheriff M.Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology.Expert Opin Ther Targets2021;25:329-33

[19] Hacein-Bey-Abina S,Schmidt M.LMO₂-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.Science2003;302:415-9

[20] High KA.Gene therapy.N Engl J Med2019;381:455-64

[21] Stratton MR,Futreal PA.The cancer genome.Nature2009;458:719-24

[22] Catalona WJ,Ratliff TL.Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.N Engl J Med1991;324:1156-61

[23] Cooperberg MR,Carroll PR.Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.J Natl Cancer Inst2009;101:878-87 PMCID:PMC2697208

[24] Koeneman KS,Ko SC.Osteocalcin-directed gene therapy for prostate-cancer bone metastasis.World J Urol2000;18:102-10

[25] Madan RA.Finding an immunologic beachhead in the prostate cancer microenvironment.J Natl Cancer Inst2019;111:219-20 PMCID:PMC6657437

[26] Liu G,Wang X.Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.J Clin Invest2013;123:4410-22 PMCID:PMC3784540

[27] Wu JD,Steinle A,Haugk K.Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.J Clin Invest2004;114:560-8 PMCID:PMC503776

[28] Healy CG,Carducci MA.Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer.Cytometry1998;32:109-19

[29] Pal SK,Won H.Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and/or enzalutamide therapy.Int J Mol Sci2019;20:1831

[30] Lopez-Bujanda Z.Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies.J Leukoc Biol2017;102:393-406 PMCID:PMC6608078

[31] Idorn M,Kongsted P,Thor Straten P.Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.Cancer Immunol Immunother2014;63:1177-87

[32] Chi N,Ma K,Yun Z.Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer.Int J Clin Exp Med2014;7:3181-92 PMCID:PMC4238489

[33] Calagua C,Sun Y.Expression of PD-L1 in hormone-naïve and Treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide.Clin Cancer Res2017;23:6812-22

[34] Shariat SF,Andrews B.Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma.Cancer2001;92:2985-92

[35] Miller AM,Ozenci V.CD4⁺CD25^high T cells are enriched in the tumor and peripheral blood of prostate cancer patients.J Immunol2006;177:7398-405

[36] Yokokawa J,Remondo C.Enhanced functionality of CD4⁺CD25^highFoxP3⁺ regulatory T cells in the peripheral blood of patients with prostate cancer.Clin Cancer Res2008;14:1032-40

[37] Getnet D,Hipkiss EL.Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.J Immunol2009;182:4675-85 PMCID:PMC3082355

[38] Ostrand-Rosenberg S.Myeloid-derived suppressor cells: linking inflammation and cancer.J Immunol2009;182:4499-506 PMCID:PMC2810498

[39] Zlotta AR,Pushkar D.Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.J Natl Cancer Inst2013;105:1050-8

[40] Whittemore AS,Feldman D.Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans.J Urol2005;174:872-6; discussion 876

[41] Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors.J Immunother Cancer2018;6:157 PMCID:PMC6307306

[42] Perera MPJ,Risbridger GP.Chimeric antigen receptor T-Cell therapy in metastatic castrate-resistant prostate cancer.Cancers2022;14:503 PMCID:PMC8833489

[43] Mughees M,Sharma G,Batra SK.Chemokines and cytokines: axis and allies in prostate cancer pathogenesis.Semin Cancer Biol2022;86:497-512 PMCID:PMC9793433

[44] Drake CG,Pardoll DM.Mechanisms of immune evasion by tumors.Adv Immunol2006;90:51-81

[45] Tien AH,Helgason CD.Altered immunity accompanies disease progression in a mouse model of prostate dysplasia.Cancer Res2005;65:2947-55

[46] Gabrilovich DI.Myeloid-derived suppressor cells.Cancer Immunol Res2017;5:3-8 PMCID:PMC5426480

[47] Gabrilovich DI.Myeloid-derived suppressor cells as regulators of the immune system.Nat Rev Immunol2009;9:162-74 PMCID:PMC2828349

[48] Mortezaee K.Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.Life Sci2021;277:119627

[49] Kozin SV,Huang Y,Jain RK.Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.Cancer Res2010;70:5679-85 PMCID:PMC2918387

[50] Levy DE.Stats: transcriptional control and biological impact.Nat Rev Mol Cell Biol2002;3:651-62

[51] Vuk-Pavlović S,Lin Y.Immunosuppressive CD14⁺HLA-DR^low/- monocytes in prostate cancer.Prostate2010;70:443-55 PMCID:PMC2935631

[52] Gustafson MP,League SC.Loss of HLA-DR expression on CD14+cells; A common marker of immunosuppression in cancer patients.J Immunother2010;33:869-70Available from: https://www.researchgate.net/publication/295679244_Loss_of_HLA-DR_Expression_on_CD14Cells_A_Common_Marker_of_Immunosuppression_in_Cancer_Patients [Last accessed on 12 Apr 2024]

[53] Pili R,Stadler WM.Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.J Clin Oncol2011;29:4022-8

[54] Björk P,Vogl T.Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.PLoS Biol2009;7:e97 PMCID:PMC2671563

[55] Murdoch C,Coffelt SB.The role of myeloid cells in the promotion of tumour angiogenesis.Nat Rev Cancer2008;8:618-31

[56] Thakur A,Lum LG.Immunotherapy and immune evasion in prostate cancer.Cancers2013;5:569-90 PMCID:PMC3730318

[57] Rabinovich GA,Sotomayor EM.Immunosuppressive strategies that are mediated by tumor cells.Annu Rev Immunol2007;25:267-96 PMCID:PMC2895922

[58] Vanneman M.Combining immunotherapy and targeted therapies in cancer treatment.Nat Rev Cancer2012;12:237-51 PMCID:PMC3967236

[59] Balachandran VP,Zeng S.Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.Nat Med2011;17:1094-100 PMCID:PMC3278279

[60] Ozao-Choy J,Kao J.The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.Cancer Res2009;69:2514-22 PMCID:PMC4370269

[61] Ghiringhelli F,Schmitt E.CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.Eur J Immunol2004;34:336-44

[62] Suzuki E,Jassar AS,Albelda SM.Gemcitabine selectively eliminates splenic Gr-1⁺/CD11b⁺ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.Clin Cancer Res2005;11:6713-21

[63] Hurwitz AA,Kwon ED.Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.Cancer Res2000;60:2444-8

[64] Hiura T,Miura S.Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.J Immunol2005;175:5058-66

[65] Tang S,Grayson JM.Increased CD8⁺ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.Cancer Res2012;72:1975-85 PMCID:PMC3690568

[66] Vergati M,Madan RA.Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.Cancer Immunol Immunother2011;60:197-206 PMCID:PMC3202216

[67] Derhovanessian E,Hähnel K.Pretreatment frequency of circulating IL-17⁺ CD4⁺ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients.Int J Cancer2009;125:1372-9

[68] Green DR,Zitvogel L.Immunogenic and tolerogenic cell death.Nat Rev Immunol2009;9:353-63 PMCID:PMC2818721

[69] Lundwall A.Molecular cloning of human prostate specific antigen cDNA.FEBS Lett1987;214:317-22

[70] Ruan H,Tao Z.Flightless I homolog reverses enzalutamide resistance through PD-L1-mediated immune evasion in prostate cancer.Cancer Immunol Res2021;9:838-52

[71] Oesterling JE.Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.J Urol1991;145:907-23

[72] Balk SP,Bubley GJ.Biology of prostate-specific antigen.J Clin Oncol2003;21:383-91

[73] Freedland SJ,Fitzsimons NJ.PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes-results from the SEARCH database.Eur Urol2008;53:758-64; discussion 765

[74] Xue B,Sosman JA.Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.Prostate1997;30:73-8

[75] Correale P,Zaremba S.In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.J Natl Cancer Inst1997;89:293-300

[76] Perambakam S,Sosman JA.Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.Cancer Immunol Immunother2002;51:263-70

[77] Terasawa H,Gulley J,Schlom J.Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.Clin Cancer Res2002;8:41-53

[78] Heiser A,Yancey DR.Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.J Immunol2000;164:5508-14

[79] Correale P,Zaremba S,Schlom J.Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.J Immunol1998;161:3186-94

[80] Harada M,Matsueda S,Noguchi M.Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24⁺ prostate cancer patients.Prostate2003;57:152-9

[81] Gotoh M,Harada K.Development of HLA-A2402/K^b transgenic mice.Int J Cancer2002;100:565-70

[82] Corman JM,Nanda NK.Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells.Clin Exp Immunol1998;114:166-72 PMCID:PMC1905118

[83] Matsueda S,Yao A.Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.Clin Cancer Res2005;11:6933-43

[84] Klyushnenkova EN,Oberle WT.Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.Clin Cancer Res2005;11:2853-61

[85] Mahadevan M,You C.Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus.Cancer Immunol Immunother2007;56:1615-24

[86] Arredouani MS,Hollenbeck BK.Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.Prostate2010;70:1002-11 PMCID:PMC2875372

[87] Drake CG,Mihalyo MA.Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.Cancer Cell2005;7:239-49 PMCID:PMC2846360

[88] Cornford P,Briers E.Eau-Eanm-Estro-Esur-Siog guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer.Eur Urol2021;79:263-82

[89] Just J,Knight C.Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise?.Br J Gen Pract2018;68:541-2 PMCID:PMC6193782

[90] Troyer JK,Wright GL Jr.Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids.Int J Cancer1995;62:552-8

[91] Israeli RS,Corr JG,Heston WD.Expression of the prostate specific membrane antigen.Cancer Res1994;54:1807-11

[92] Sokoloff RL,Gasior CL,Grauer LS.A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine.Prostate2000;43:150-7

[93] Murphy GP,Su SL,Holmes EH.Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.Cancer1998;83:2259-69

[94] Kawakami M.Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization.Cancer Res1997;57:2321-4

[95] Kuang Y,Liu X.Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.Cancer Lett2010;293:254-62

[96] George DJ.An α-particle emitting antibody ([²¹³Bi]J591) for radioimmunotherapy of prostate cancer.Prostate2001;3:1

[97] Fracasso G,Cingarlini S.Anti-tumor effects of toxins targeted to the prostate specific membrane antigen.Prostate2002;53:9-23

[98] Vallabhajosula S,Navarro V,Bander NH.Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.Prostate2004;58:145-55

[99] Carroll PR.Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor: Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH, Division of nuclear medicine, department of radiology, New York presbyterian Hospital-Weill Medical College of Cornell University, New York, NY. J Nucl Med 2003;44:610-617.Urol Oncol-Semin Origin Invest2003;21:486-7

[100] Kuroda K,Kim S,Navarro V.Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.Prostate2010;70:1286-94

[101] Sartor O.Prostate specific membrane antigen binding radiopharmaceuticals: current data and new concepts.Front Med2022;9:1060922 PMCID:PMC9763319

[102] Solin T,Pohlmann R.Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses.Biochim Biophys Acta1990;1048:72-7

[103] Cunha AC,Kiessling A,Rieber EP.Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues.Cancer Lett2006;236:229-38

[104] Graddis TJ,Tamman J,Trager JB.Prostatic acid phosphatase expression in human tissues.Int J Clin Exp Pathol2011;4:295-306 PMCID:PMC3071662

[105] Machlenkin A,Bar Haim E.Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.Cancer Res2005;65:6435-42

[106] Machlenkin A,Volovitz I.Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.Cancer Immunol Immunother2007;56:217-26

[107] Olson BM,Johnson LE.HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.Cancer Immunol Immunother2010;59:943-53 PMCID:PMC3038205

[108] Spies E,Alvarez G,Ohlschläger P.An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma.Mol Ther2012;20:555-64 PMCID:PMC3293618

[109] Kantoff PW,Shore ND.Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med2010;363:411-22

[110] Kiessling A,Füssel S,Wirth MP.Tumor-associated antigens for specific immunotherapy of prostate cancer.Cancers2012;4:193-217 PMCID:PMC3712678

[111] Tannock IF,Berry WR.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med2004;351:1502-12

[112] Schellhammer PF,Whitmore JB,Frohlich MW.Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.Urology2013;81:1297-302

[113] Scher HI,Saad F.Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med2012;367:1187-97

[114] Petrylak DP,Hussain MH.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med2004;351:1513-20

[115] Sheikh NA,Kantoff PW.Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.Cancer Immunol Immunother2013;62:137-47 PMCID:PMC3541926

[116] McNeel DG,Eickhoff JC.Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.Clin Cancer Res2014;20:3692-704 PMCID:PMC4102643

[117] de Bono JS,Ozguroglu M.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.Lancet2010;376:1147-54

[118] Parker C,Heinrich D.Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med2013;369:213-23

[119] Wargowski E,Eickhoff JC.Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.J Immunother Cancer2018;6:21 PMCID:PMC5850960

[120] Dannull J,Prikler L.Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.Cancer Res2000;60:5522-8

[121] Kiessling A,Stevanovic S.Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8⁺ T cells in prostate cancer patients.Int J Cancer2002;102:390-7

[122] Matsueda S,Nonaka Y,Itoh K.Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2⁺ patients with hormone-refractory prostate cancer.Cancer Immunol Immunother2004;53:479-89

[123] Matsueda S,Ishihara Y.A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.Prostate2004;60:205-13

[124] de la Luz Garcia-Hernandez M, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.Cancer Res2008;68:861-9

[125] Krupa M,Gomez CE,Gil J.Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.Vaccine2011;29:1504-13

[126] Ross S,Holcomb I.Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.Cancer Res2002;62:2546-53

[127] Saffran DC,Hubert RS,Reiter RE.Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.Proc Natl Acad Sci USA2001;98:2658-63 PMCID:PMC30194

[128] Gu Z,Kono E.Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism.Cancer Res2005;65:9495-500

[129] Olafsen T,Sherman MA.Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.J Immunother2007;30:396-405

[130] Feldmann A,Bippes CC.Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats.Prostate2011;71:998-1011

[131] Morgenroth A,Schmitz M.Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.Prostate2007;67:1121-31

[132] Murad JP,Park AK.Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.Mol Ther2021;29:2335-49 PMCID:PMC8261088

[133] Dorff TB,Forman SJ.Novel redirected T-cell immunotherapies for advanced prostate cancer.Clin Cancer Res2022;28:576-84 PMCID:PMC8866199

[134] Hempelmann JA,Konnick EQ.Microsatellite instability in prostate cancer by PCR or next-generation sequencing.J Immunother Cancer2018;6:29

[135] Fraune C,Höflmayer D.High homogeneity of mismatch repair deficiency in advanced prostate cancer.Virchows Arch2020;476:745-52

[136] Abida W,Armenia J.Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade.JAMA Oncol2019;5:471-8 PMCID:PMC6459218

[137] Xu J,Stolk JA.Identification and characterization of prostein, a novel prostate-specific protein.Cancer Res2001;61:1563-8

[138] Kalos M,Hylander BL.Prostein expression is highly restricted to normal and malignant prostate tissues.Prostate2004;60:246-56

[139] Musiyenko A,Barik S.Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells.J Mol Med2008;86:313-22 PMCID:PMC3263384

[140] Kiessling A,Füssel S.Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.Br J Cancer2004;90:1034-40 PMCID:PMC2410218

[141] Schmidt U,Koch R.Quantitative multi-gene expression profiling of primary prostate cancer.Prostate2006;66:1521-34

[142] Friedman RS,Kalos M.Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate.Eur J Immunol2004;34:1091-101

[143] Swaya TO,Atandi DO,Magak NWG.Immunohistochemical analysis of prostein in needle core biopsies of acinar and intraductal prostatic adenocarcinoma in Western Kenya population.J Cancer Sci Clin Ther2022;6:269-75Available from: https://repository.maseno.ac.ke/handle/123456789/5358 [Last accessed on 12 Apr 2024].

[144] Wolfgang CD,Vincent JJ,Pastan I.TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus.Proc Natl Acad Sci USA2000;97:9437-42 PMCID:PMC16882

[145] Cheng WS,Pastan I.Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter.Endocrinology2003;144:3433-40

[146] Maeda H,Wolfgang CD,Bera TK.The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria.J Biol Chem2004;279:24561-8

[147] Carlsson B,Essand M.Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP.Prostate2004;61:161-70

[148] Oh S,Pendleton CD.Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.Cancer Res2004;64:2610-8

[149] Kobayashi H,Oikawa K.Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.Clin Cancer Res2005;11:3869-78 PMCID:PMC1594816

[150] Epel M,Soueid-Baumgarten S.Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.Eur J Immunol2008;38:1706-20 PMCID:PMC2682370

[151] Hillerdal V,Carlsson B,Essand M.T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2⁺ prostate and breast cancer cells.Proc Natl Acad Sci USA2012;109:15877-81 PMCID:PMC3465394

[152] Hillerdal V,Björkelund H,Essand M.Avidity characterization of genetically engineered T-cells with novel and established approaches.BMC Immunol2016;17:23 PMCID:PMC4944473

[153] Bonte S,Goetgeluk G.T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources.Oncoimmunology2020;9:1727078 PMCID:PMC7028335

[154] Vanhooren J,Depreter B.TARP as antigen in cancer immunotherapy.Cancer Immunol Immunother2021;70:3061-8 PMCID:PMC8164403

[155] Tsavaler L,Morkowski S.Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins.Cancer Res2001;61:3760-9

[156] Ochoa SV,Albarracín SL,Torres YP.Therapeutic potential of TRPM8 channels in cancer treatment.Front Pharmacol2023;14:1098448 PMCID:PMC10073478

[157] Zhang L.TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function?.Endocr Relat Cancer2006;13:27-38

[158] Bidaux G,Merle C.Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement.Endocr Relat Cancer2005;12:367-82

[159] Valero M,Belmonte C.Pharmacological and functional properties of TRPM8 channels in prostate tumor cells.Pflugers Arch2011;461:99-114

[160] Kiessling A,Schmitz M.Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8.Prostate2003;56:270-9

[161] Xu M,Bizzaro CL.STEAP1-4 (six-transmembrane epithelial antigen of the prostate 1-4) and their clinical implications for prostate cancer.Cancers2022;14:4034 PMCID:PMC9406800

[162] Jiao Z,Sun J.Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition.Histochem Cell Biol2020;154:215-30

[163] Santos C,Maia CJ. STEAP1 (six transmembrane epithelial antigene of the prostate 1). 2009. Available from: https://ubibliorum.ubi.pt/bitstream/10400.6/7635/1/STEAP1%20%28Six%20Transmembrane%20Epithelial%20Antigene.pdf [Last accessed on 12 Apr 2024]

[164] Rodeberg DA,Elsawa SF.Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.Clin Cancer Res2005;11:4545-52 PMCID:PMC1698136

[165] Alves PM,Graff-Dubois S.STEAP, a prostate tumor antigen, is a target of human CD8⁺ T cells.Cancer Immunol Immunother2006;55:1515-23

[166] Kobayashi H,Sato K.Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.Cancer Res2007;67:5498-504

[167] Azumi M,Aoki N.Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.J Urol2010;183:2036-44

[168] Hayashi S,Matsuda Y.Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.J Transl Med2011;9:191 PMCID:PMC3219573

[169] de la Luz Garcia-Hernandez M, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.Cancer Res2007;67:1344-51

[170] Kim S,Lee GK.Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.Prostate2009;69:938-48

[171] Challita-Eid PM,Etessami S.Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo.Cancer Res2007;67:5798-805

[172] Gati A,Derouiche A,Chebil M.NY-ESO-1 expression and immunogenicity in prostate cancer patients.Tunis Med2011;89:779-83

[173] Thomas R,Roelands J.NY-ESO-1 based immunotherapy of cancer: current perspectives.Front Immunol2018;9:947 PMCID:PMC5941317

[174] Nakada T,Satoh S.NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.Cancer Immun2003;3:10

[175] Karbach J,Atmaca A.Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients.Clin Cancer Res2011;17:861-70

[176] Guise TA.Parathyroid hormone‐related protein and bone metastases.Cancer1997;80:1572-80

[177] Arima Y,Yano H,Itoh K.Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types.Int J Oncol2005;27:981-8

[178] Edwards CM.From good to bad: the opposing effects of PTHrP on tumor growth, dormancy, and metastasis throughout cancer progression.Front Oncol2021;11:644303 PMCID:PMC8019909

[179] Asadi F.Parathyroid hormone-related protein in prostate cancer.Crit Rev Eukaryot Gene Expr2005;15:15-28

[180] Kim NW,Prowse KR.Specific association of human telomerase activity with immortal cells and cancer.Science1994;266:2011-5

[181] Adotévi O,Neuveut C.Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.Clin Cancer Res2006;12:3158-67

[182] Negrini S,Filaci G.Anti-cancer immunotherapies targeting telomerase.Cancers2020;12:2260 PMCID:PMC7465444

[183] Huo LF,Huang JJ.Cancer immunotherapy targeting the telomerase reverse transcriptase.Cell Mol Immunol2006;3:1-11

[184] Leão R,Lee D,Tabori U.Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.J Biomed Sci2018;25:22 PMCID:PMC5846307

[185] Esquenazi Y.Telomerase reverse transcriptase alterations in human cancers: diagnosis, prognosis, and therapeutic implications.Cancer Cytopathol2019;127:275-7

[186] Yang R,Guan X.Regulation and clinical potential of telomerase reverse transcriptase (TERT/hTERT) in breast cancer.Cell Commun Signal2023;21:218 PMCID:PMC10463831

[187] Ryan BM,Duffy MJ.Survivin: a new target for anti-cancer therapy.Cancer Treat Rev2009;35:553-62

[188] Zhang M,Delaney MA.Survivin mediates resistance to antiandrogen therapy in prostate cancer.Oncogene2005;24:2474-82

[189] Xiang R,Luo Y.A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication.Cancer Res2005;65:553-61

[190] Ciesielski MJ,Castanaro CA,Fenstermaker RA.Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.Cancer Immunol Immunother2008;57:1827-35 PMCID:PMC2572859

[191] Li F,Ling X.Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?.J Exp Clin Cancer Res2019;38:368 PMCID:PMC6704566

[192] Garg H,Gupta JC,Dubey S.Survivin: a unique target for tumor therapy.Cancer Cell Int2016;16:49 PMCID:PMC4917988

[193] Di Lorenzo G,De Laurentiis M.HER-2/neu receptor in prostate cancer development and progression to androgen independence.Tumori2004;90:163-70

[194] Neto AS,Wroclawski ML.Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis.J Urol2010;184:842-50

[195] Baxevanis CN,Gritzapis AD,Papamichail M.HER-2/neu as a target for cancer vaccines.Immunotherapy2010;2:213-26

[196] Agus DB,Higgins B.Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.Cancer Res1999;59:4761-4

[197] Formento P,Gérard F.Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.Eur J Cancer2005;41:1467-73

[198] Pinthus JH,Malina V.Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.J Clin Invest2004;114:1774-81 PMCID:PMC535069

[199] De Muga S,Agell L.Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.Mod Pathol2010;23:703-12

[200] Filho PA, López-Albaitero A, Gooding W, Ferris RL. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.J Immunother2010;33:83-91 PMCID:PMC3695408

[201] Vexler A,Loew V.Anti-ErbB4 targeting approaches for prostate cancer treatment.Cancer Biol Ther2008;7:1090-4

[202] Richards L.Genetics: N-cadherin - a target for prostate cancer therapy.Nat Rev Clin Oncol2011;8:63

[203] Tanaka H,Tran CP.Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.Nat Med2010;16:1414-20 PMCID:PMC3088104

[204] Cui Y.N-cadherin dependent collective cell invasion of prostate cancer cells is regulated by the N-terminus of α-catenin.PLoS One2013;8:e55069 PMCID:PMC3554680

[205] Jennbacken K,Wang W,Damber JE.N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.Endocr Relat Cancer2010;17:469-79

[206] Tandon M,Mittal SK.Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Expert Opin Ther Targets2011;15:31-51 PMCID:PMC3016619

[207] Colapietro A,Petragnano F.Antitumorigenic effects of inhibiting ephrin receptor kinase signaling by GLPG1790 against colorectal cancer cell lines in vitro and in vivo.J Oncol2020;2020:9342732 PMCID:PMC7063197

[208] Chang FL,Lin TY,Pan SL.Effectiveness of anti-erythropoietin producing hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment.Heliyon2023;9:e21774 PMCID:PMC10682614

[209] Yamaguchi S,Takehara T.Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.Cancer2007;110:1469-77

[210] Peng L,Damschroder MM,Dall’Acqua WF.Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody.J Mol Biol2011;413:390-405

[211] Lee JW,Lee SJ.EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.Clin Cancer Res2010;16:2562-70 PMCID:PMC3955167

[212] Smith HA,Lang JM.Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.Cancer Res2011;71:6785-95

[213] Hale R,Shipley J.Epigenetic targets in synovial sarcoma: a mini-review.Front Oncol2019;9:1078 PMCID:PMC6813544

[214] Smith HA.The SSX family of cancer-testis antigens as target proteins for tumor therapy.Clin Dev Immunol2010;2010:150591 PMCID:PMC2963798

[215] Smith HA.Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.J Immunother2011;34:569-80 PMCID:PMC3175298

[216] Liao Y,Jia Y,Li X.EpCAM as a novel biomarker for survivals in prostate cancer patients.Front Cell Dev Biol2022;10:843604 PMCID:PMC9065552

[217] Ni J,Beretov J.Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo.BMC Cancer2018;18:1092 PMCID:PMC6233586

[218] Rybalov M,Hoving HD,Rosati S.PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy.Int J Mol Sci2014;15:6046-61 PMCID:PMC4013614

[219] Yan Y,Qian C.RIPK2 stabilizes c-Myc and is an actionable target for inhibiting prostate cancer metastasis. bioRxiv 2020

[220] Yan Y,Qian C.Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.Nat Commun2022;13:669 PMCID:PMC8813925

[221] You J,Chen H.RIPK2: a promising target for cancer treatment.Front Pharmacol2023;14:1192970 PMCID:PMC10266216

[222] Galon J.Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.Nat Rev Drug Discov2019;18:197-218

[223] Karpf AR,James SR,Wilson EM.Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.Mol Cancer Res2009;7:523-35 PMCID:PMC2670465

[224] Bai S.Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor.Mol Cell Biol2008;28:1947-63 PMCID:PMC2268407

[225] Su S,Grossman G,Wang Z.Up-regulation of follistatin-like 1 by the androgen receptor and melanoma Antigen-A11 in prostate cancer.Prostate2017;77:505-16

[226] Bai S,Wilson EM.Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction.Mol Cell Biol2005;25:1238-57 PMCID:PMC548016

[227] Weon JL.The MAGE protein family and cancer.Curr Opin Cell Biol2015;37:1-8 PMCID:PMC4688208

[228] Gasser S,Cheung FSG.The role of the tumour microenvironment in immunotherapy.Endocr Relat Cancer2017;24:T283-95

[229] Stultz J.How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.Prostate Cancer Prostatic Dis2021;24:697-717 PMCID:PMC8384622

[230] Wu Z,Luo W.The landscape of immune cells infiltrating in prostate cancer.Front Oncol2020;10:517637 PMCID:PMC7658630

[231] Di Mitri D,Vasilevska J.Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer.Cell Rep2019;28:2156-68.e5 PMCID:PMC6715643

[232] Ollivier L,Fradin D,Supiot S.Interaction between modern radiotherapy and immunotherapy for metastatic prostate cancer.Front Oncol2021;11:744679 PMCID:PMC8477651

[233] Hess KR,Taylor SH.Metastatic patterns in adenocarcinoma.Cancer2006;106:1624-33

[234] Xiang L.The contribution of the immune system in bone metastasis pathogenesis.Int J Mol Sci2019;20:999 PMCID:PMC6412551

[235] Kim SW,Papadopoulos J.Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.Int Immunopharmacol2011;11:862-72 PMCID:PMC3086935

[236] Jiao S,Aparicio A.Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy.Cell2019;179:1177-90.e13

[237] Tan Y,Zhang Y.Tumor-associated macrophages: a potential target for cancer therapy.Front Oncol2021;11:693517 PMCID:PMC8222665

[238] Kumari N.Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies.J Exp Clin Cancer Res2022;41:68 PMCID:PMC8857848

[239] Sleeman JP.The lymph node pre-metastatic niche.J Mol Med2015;93:1173-84

[240] Ioannidou E,Shah S.Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and molecular targets.Int J Mol Sci2021;22:9926 PMCID:PMC8472415

[241] Sharma V,Kwon E.Positive pelvic lymph nodes in prostate cancer harbor immune suppressor cells to impair tumor-reactive T cells.Eur Urol Focus2018;4:75-9

[242] Chen S,Yang Y.Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.Nat Cell Biol2021;23:87-98

[243] Klusa D,Furesi G.Metastatic spread in prostate cancer patients influencing radiotherapy response.Front Oncol2020;10:627379 PMCID:PMC7971112

[244] He ZN,Zhao YW.Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer.Discov Oncol2023;14:185 PMCID:PMC10587041

[245] Venkatachalam S,Agarwal N.Immune checkpoint inhibitors in prostate cancer.Cancers2021;13:2187 PMCID:PMC8125096

[246] Gonzalez-Velez M.How to approach immune checkpoint inhibitor therapy in prostate cancer.Urol Times Urologists Cancer Care2020;9:Available from: https://www.urologytimes.com/view/how-to-approach-immune-checkpoint-inhibitor-therapy-in-prostate-cancer [Last accessed on 29 Mar 2024]

[247] Wong YNS,Josephs DH.Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).J Clin Oncol2019;37:tps5090

[248] Carbognin L,Milella M.Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers.PLoS One2015;10:e0130142 PMCID:PMC4472786

[249] Sato H,Yasuhara T.DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.Nat Commun2017;8:1751 PMCID:PMC5701012

[250] Subudhi SK,Zhao H.Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.Sci Transl Med2020;12:eaaz3577

[251] Beer TM,Drake CG.Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer.J Clin Oncol2017;35:40-7

[252] Kwon ED,Scher HI.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.Lancet Oncol2014;15:700-12

[253] Graff JN,Liang LW.Phase III study of pembrolizumab (Pembro) plus enzalutamide (Enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641.J Clin Oncol2020;38:TPS258

[254] Antonarakis ES,Goh JC.Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial.J Clin Oncol2023;41:3839-50 PMCID:PMC10419579

[255] Petrylak DP,Matsubara N.Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): randomized, double-blind, phase 3 KEYNOTE-921 study.J Clin Oncol2023;41:19

[256] Powles T,Gillessen S.Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.Nat Med2022;28:144-53 PMCID:PMC9406237

[257] Fizazi K,Castellano D.Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.Eur J Cancer2022;160:61-71

[258] Meng L,Mortazavi A.Emerging immunotherapy approaches for treating prostate cancer.Int J Mol Sci2023;24:14347 PMCID:PMC10531627

[259] Hansen AR,Ott PA.Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.Ann Oncol2018;29:1807-13

[260] Antonarakis ES,Gross-Goupil M.Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study.J Clin Oncol2020;38:395-405

[261] Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.Expert Rev Clin Pharmacol2018;11:475-86 PMCID:PMC6317331

[262] Wang S,Liu T.Cancer immunotherapies: from efficacy to resistance mechanisms - not only checkpoint matters.Front Immunol2021;12:690112 PMCID:PMC8335396

[263] Liang H,Guo J.Progression in immunotherapy for advanced prostate cancer.Front Oncol2023;13:1126752 PMCID:PMC10011447

[264] King A.Could immunotherapy finally break through in prostate cancer?.Nature2022;609:S42-4

[265] Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer.Nat Rev Clin Oncol2011;8:551-61

[266] Galsky MD.Resistance to prostate-cancer treatment is driven by immune cells.Nature2018;559:338-9

[267] Belete TM.The current status of gene therapy for the treatment of cancer.Biologics2021;15:67-77 PMCID:PMC7987258

[268] Edwards BK,Mariotto AB.Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.Cancer2014;120:1290-314

[269] National Cancer Institute. NCI comorbidity index overview. Available from: https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html [Last accessed on 28 Mar 2024]

[270] Klabunde CN,Legler JM.Development of a comorbidity index using physician claims data.J Clin Epidemiol2000;53:1258-67

[271] Asmar R,Korgavkar K,Cooney KA.Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.Prostate Cancer Prostatic Dis2013;16:62-6 PMCID:PMC3860174

[272] Post JM,Morgenstern H.The metabolic syndrome and biochemical recurrence following radical prostatectomy.Prostate Cancer2011;2011:245642 PMCID:PMC3196931

[273] Jefferson M,Lilly M,Tucker Price S.Co-morbidities in a retrospective cohort of prostate cancer patients.Ethn Dis2020;30:185-92 PMCID:PMC7138439

[274] Boussios S,Samartzis E.Melanoma of unknown primary: new perspectives for an old story.Crit Rev Oncol Hematol2021;158:103208

[275] Sharma AR,Nam JS.Next generation delivery system for proteins and genes of therapeutic purpose: why and how?.Biomed Res Int2014;2014:327950 PMCID:PMC4122142

[276] Templeton NS, editor. Gene and cell therapy: therapeutic mechanisms and strategies. CRC Press; 2008.

[277] Colella P,Mingozzi F.Emerging issues in AAV-mediated in vivo gene therapy.Mol Ther Methods Clin Dev2018;8:87-104 PMCID:PMC5758940

[278] Merten OW,Laroudie N.Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application.Hum Gene Ther2011;22:343-56

[279] Huang C,Wu J,Wang X.Identification of pathogenic variants in cancer genes using base editing screens with editing efficiency correction.Genome Biol2021;22:80 PMCID:PMC7945310

[280] Zhang H,An C.Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer.Mol Cancer2021;20:126 PMCID:PMC8484294

[281] Palpant NJ.Zinc finger nucleases: looking toward translation.Gene Ther2013;20:121-7

[282] Cassandri M,Novelli F.Zinc-finger proteins in health and disease.Cell Death Discov2017;3:17071 PMCID:PMC5683310

[283] Shojaei Baghini S,Abadi SAH.CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.Cell Mol Biol Lett2022;27:35 PMCID:PMC9066929

[284] Hille F,Wong SP,Ressel S.The biology of CRISPR-Cas: backward and forward.Cell2018;172:1239-59

[285] Li Y,Huang M,Xu Q.Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.Biomaterials2020;234:119711 PMCID:PMC7035593

[286] Sun N.Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing.Biotechnol Bioeng2013;110:1811-21

[287] Nakano C,Takeyari S.Genetic correction of induced pluripotent stem cells mediated by transcription activator-like effector nucleases targeting ALPL recovers enzyme activity and calcification in vitro.Mol Genet Metab2019;127:158-65

[288] Lundstrom K.Viral vectors in gene therapy: where do we stand in 2023?.Viruses2023;15:698 PMCID:PMC10059137

[289] Bin Umair M,Kashif H.Viruses as tools in gene therapy, vaccine development, and cancer treatment.Arch Virol2022;167:1387-404 PMCID:PMC9035288

[290] Sung YK.Recent advances in the development of gene delivery systems.Biomater Res2019;23:8 PMCID:PMC6417261

[291] Sung YK.The practical application of gene vectors in cancer therapy.Integrat Cancer Sci Therap2018;5:1-5

[292] Panday R,Neupane M,Kricha A.Advances in magnetic nanoparticle-driven delivery of gene therapies towards prostate cancer.J Nanomater2021;2021:6050795

[293] Altwaijry N,Dufès C.Targeted nonviral gene therapy in prostate cancer.Int J Nanomed2018;13:5753-67 PMCID:PMC6165780

[294] Rehman K,Zhiqin D.Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer.Cancer Cell Int2023;23:247 PMCID:PMC10585889

[295] Ahmed KA,Wilson TM,Federspiel MJ.Progress in gene therapy for prostate cancer.Front Oncol2012;2:172 PMCID:PMC3500761

[296] Naseer F,Kousar K.Advanced therapeutic options for treatment of metastatic castration resistant prostatic adenocarcinoma.Front Pharmacol2021;12:728054 PMCID:PMC8660108

[297] Yin H,Anderson DG.Delivery technologies for genome editing.Nat Rev Drug Discov2017;16:387-99

[298] Planul A.Vectors and gene delivery to the retina.Annu Rev Vis Sci2017;3:121-40

[299] Hill AB,Chen CK,Jones CH.Overcoming gene-delivery hurdles: physiological considerations for nonviral vectors.Trends Biotechnol2016;34:91-105 PMCID:PMC5800990

[300] Zhang Y,Huang L.In vivo gene delivery by nonviral vectors: overcoming hurdles?.Mol Ther2012;20:1298-304 PMCID:PMC3392980

[301] Butt MH,Ahmad A.Appraisal for the potential of viral and nonviral vectors in gene therapy: a review.Genes2022;13:1370 PMCID:PMC9407213

[302] Dey D.Suicide gene therapy by herpes simplex virus-1 thymidine kinase (HSV-TK).Targets Gene Ther2011;65

[303] Harrison GS.Current challenges of gene therapy for prostate cancer.Oncology1997;11:845-55

[304] Han C,Xu W.The roles of tumor-associated macrophages in prostate cancer.J Oncol2022;2022:8580043 PMCID:PMC9473905

[305] Msaouel P,Allen C.Engineered measles virus as a novel oncolytic therapy against prostate cancer.Prostate2009;69:82-91 PMCID:PMC2737678

[306] Li J,He M,Murthy N.Non-viral strategies for delivering genome editing enzymes.Adv Drug Deliv Rev2021;168:99-117

[307] Gregg JR.Considering the potential for gene-based therapy in prostate cancer.Nat Rev Urol2021;18:170-84

[308] van Ophoven A, Ng CP, Patel B, Bonavida B, Belldegrun A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature.Prostate Cancer Prostatic Dis1999;2:227-33

[309] Darvish L,Aghaee-Bakhtiari SH.Inducing apoptosis by using microRNA in radio-resistant prostate cancer: an in-silico study with an in-vitro validation.Mol Biol Rep2023;50:6063-74

[310] Teh BS,Mai WY,Butler EB.Long-term outcome of a phase II trial using immunomodulatory in situ gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy in the treatment of prostate cancer.Int J Radiat Oncol2015;4:377-86

[311] Boettcher AN,Morgans A,Sosman J.Past, current, and future of immunotherapies for prostate cancer.Front Oncol2019;9:884 PMCID:PMC6749031

[312] LeVee A,Posadas E.Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: a review of current evidence and patient selection.Onco Targets Ther2021;14:4819-32 PMCID:PMC8450162

[313] Powers E,Kao C.Novel therapies are changing treatment paradigms in metastatic prostate cancer.J Hematol Oncol2020;13:144 PMCID:PMC7594418

[314] Gdor Y,Kadmon D,Thompson TC.Strategies for prostate cancer gene therapy.Am J Cancer2004;3:79-95

[315] Lin Y,Lächelt U.Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP.Biomater Sci2022;10:1166-92

[316] Kanvinde S,Deodhar S,Dasgupta A.Non-viral vectors for delivery of nucleic acid therapies for cancer.BioTech2022;11:6 PMCID:PMC9245904

[317] McCrudden CM,McCaffrey J.Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer.Cancer Nanotechnol2018;9:5 PMCID:PMC5982451

[318] Liu C,Russell SJ,Peng KW.Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.Prostate2009;69:1128-41 PMCID:PMC2976666

[319] Son HA,Cuong BK.Combination of vaccine-strain measles and mumps viruses enhances oncolytic activity against human solid malignancies.Cancer Invest2018;36:106-17

[320] Durso RJ,Gardner JP.A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.Clin Cancer Res2007;13:3999-4008

[321] Mansfield DC,Rosenfelder N.Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.Gene Ther2016;23:357-68 PMCID:PMC4827015

[322] Slovin SF,Durso R.A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.Vaccine2013;31:943-9

[323] Vajda A,Foley R,Lawler M.Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.Cancer Treat Rev2011;37:643-54